Products Press Releases Partnering Careers Contact

Featured Post

Temporary Shortage of Quillivant® ER 20mg Chewable Tablets

May 19, 2025

May 24, 2022

KYE Pharmaceuticals Announces John McKendry as President

March 21, 2022

KYE Pharmaceuticals Files Accrufer® New Drug Submission in Canada for the Treatment of Iron Deficiency

March 11, 2022

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

January 5, 2022

Shield Therapeutics and KYE Pharmaceuticals Inc Announce Exclusive licence agreement for development and commercialisation of Accrufer®

June 3, 2021

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®

May 4, 2021

KYE Announces Commercial Availability of CORZYNA™ (ranolazine 500 mg extended-release tablets)